A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment

OBJECTIVE: Current type 2 diabetes (T2D) management contraindicates intensive glycemia treatment in patients with high cardiovascular disease (CVD) risk and is partially motivated by evidence of harms in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Heterogeneity in response...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariam, Arshiya, Miller-Atkins, Galen, Pantalone, Kevin M., Zimmerman, Robert S., Barnard, John, Kattan, Michael W., Shah, Hetal, McLeod, Howard L., Doria, Alessandro, Wagner, Michael J., Buse, John B., Motsinger-Reif, Alison A., Rotroff, Daniel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247498/
https://www.ncbi.nlm.nih.gov/pubmed/33863751
http://dx.doi.org/10.2337/dc20-2700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247498/
https://www.ncbi.nlm.nih.gov/pubmed/33863751
http://dx.doi.org/10.2337/dc20-2700

Ejemplares similares